Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial
Executive Summary
The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.